One case series included a patient who had a kidney biopsy demonstrating acute tubular necrosis as a potential mechanism of renal injury. 4 
Methods
A waiver of institutional review board review was received for this study. We reviewed the Food and Drug Administration Adverse Event Reporting System (FAERS) 5 quarterly legacy data file from the third quarter of 2011 through second quarter of 2014 for vemurafenib and second quarter of 2013 through second quarter of 2014 for dabrafenib. Data regarding renal adverse events related to vemurafenib and dabrafenib therapy were extracted from the database through formation of a query using FAERS-assigned unique case identifiers. Search terms used were "renal insufficiency, elevated creatinine, renal failure, renal injury, proteinuria, renal impairment, blood creatinine increase, renal failure acute, low phosphorus, hypophosphatemia, hypercreatinemia, hyponatremia, hypokalemia, renal damage."
Results
A total of 132 cases of AKI in patients receiving vemurafenib therapy were reported to the FAERS during the period reviewed. Eighty-five patients were men, and 47, women (P < .001). The mean age of the men was 65 years, and of the women, 59 years (P = .04). The cases were reported from around the world, with France, the United States, and Germany reporting most of the cases. Fourteen cases of electrolyte disorders were reported (6 cases of hypokalemia and 8 cases of hyponatremia). The most common indication was for treatment of malignant melanoma. Thirteen cases of AKI in patients receiving dabrafenib therapy were reported to the FAERS during the period reviewed. Twelve patients were men. The mean age of the men was 55 years, and of the women, 75 years (P = .002). Eight cases of electrolyte disorders were reported (2 cases of hypokale-IMPORTANCE The selective BRAF inhibitors vemurafenib and dabrafenib have shown significant improvement in patient survival compared with standard therapy in BRAF V600-mutant metastatic melanoma.
OBSERVATIONS We reviewed Food and Drug Administration Adverse Event Reporting System (FAERS) data for both agents for renal toxic effects. From July 2011 through June 2014, 132 cases of acute kidney injury in patients receiving vemurafenib therapy were reported. Renal injury was more common in men (85 men vs 47 women; P < .001). From April 2013 through June 2014, 13 cases of renal injury in patients receiving dabrafenib therapy were reported (12 men and 1 woman). Hypokalemia (6 cases in patients receiving vemurafenib and 2 cases in patients receiving dabrafenib) and hyponatremia (8 and 6 cases, respectively) were also reported.
CONCLUSIONS AND RELEVANCE Vemurafenib seems to be more nephrotoxic than dabrafenib. This renal toxicity seems to be more prevalent among male patients with melanoma. On the basis of the few published case reports, the mode of injury seems to be tubular interstitial injury. Our findings suggest a need to monitor renal function and electrolyte levels in all patients who receive these drugs. Dermatologists, oncologists, and nephrologists need to be aware of this potential hazard.
